Meeting
2019 ASCO Annual Meeting
Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis.
Authors
Paul Stewart
Western University, Schulich School of Medicine and Dentistry, London, ON, Canada
Paul Stewart , Phillip S. Blanchette , Prakesh S Shah , Xiang Y Ye , R Gabriel Boldt , Ricardo Fernandes , Theodore A. Vandenberg , Jacques Raphael
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 522)
DOI
10.1200/JCO.2019.37.15_suppl.522
Abstract #
522
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.
First Author: Hadar Goldvaser
Poster
2023 ASCO Annual Meeting
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
First Author: Anna-Maria Lazaratos
Poster
2023 ASCO Annual Meeting
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis.
First Author: Chiara Molinelli
Poster
2022 ASCO Annual Meeting
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
First Author: Maria Vittoria Dieci